Last reviewed · How we verify
Amlodipine+intensive antihypertensive therapy
Amlodipine blocks L-type calcium channels in vascular smooth muscle to reduce blood pressure, often combined with other antihypertensive agents for enhanced efficacy.
Amlodipine blocks L-type calcium channels in vascular smooth muscle to reduce blood pressure, often combined with other antihypertensive agents for enhanced efficacy. Used for Hypertension (as part of intensive antihypertensive regimen), Angina pectoris.
At a glance
| Generic name | Amlodipine+intensive antihypertensive therapy |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Calcium channel blocker (dihydropyridine) |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reduced peripheral vascular resistance. When used as intensive antihypertensive therapy (typically in combination with other agents such as ACE inhibitors, ARBs, or diuretics), it provides additive blood pressure reduction through complementary mechanisms of action.
Approved indications
- Hypertension (as part of intensive antihypertensive regimen)
- Angina pectoris
Common side effects
- Peripheral edema
- Headache
- Flushing
- Dizziness
- Fatigue
Key clinical trials
- Integration of Hypertension Management in HIV Care in Uganda (NA)
- Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) (PHASE2)
- Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial) (PHASE2)
- Arterial Stiffness and Blood Pressure (NA)
- Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes (PHASE4)
- Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas (NA)
- Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal Substudy (PHASE4)
- Risk Reduction for Alzheimer's Disease (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: